Sanofi Signs Letter of Intent With Canadian Drug Alliance for Dupixent in Four Additional Indications

MT Newswires Live10-16

Sanofi (SNY) said Thursday it completed negotiations with the pan-Canadian Pharmaceutical Alliance and signed a letter of intent covering Dupixent, or dupilumab, for four additional indications.

The agreement covers pediatric atopic dermatitis, prurigo nodularis, severe chronic rhinosinusitis with nasal polyposis and chronic obstructive pulmonary disease. Sanofi said it plans to work with public payers to support access for eligible patients through public drug plans.

Dupixent is jointly developed by Sanofi and Regeneron Pharmaceuticals (REGN) and is authorized in Canada for several inflammatory conditions across different age groups, the company said.

Shares of Sanofi were up 1.4% in Thursday afternoon trading.

Price: 40.32, Change: +0.54, Percent Change: +1.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment